GuruFocus Premium Membership

Serving Intelligent Investors since 2004. Only 96 cents a day.

Free Trial

Free 7-day Trial
All Articles and Columns »

Gabelli Is Friend to FOE – Ferro Cuts Costs, Trims Non-Core and Extends Global Reach

April 23, 2013 | About:
Sally Jones

Sally Jones

49 followers
GAMCO Investors’ Chairman and Chief Executive Officer Mario Gabelli increased his position in specialty chemical company Ferro Corp. (FOE) by 20.21% as of April 23, 2013. Gabelli now holds 8,382,134 shares of FOE at a current price of $6.81 with a change from average up 1%. Gabelli bought shares in the price range of $6.76. His latest stake impacts his portfolio by 0.07%. Gabelli's holding history which began in fourth quarter 2008 has seen 18 consecutive quarters of trading with very mixed results. As of the end of fourth quarter 2012, Gabelli’s average cost on 6,972,674 shares was $9 per share with a 23% loss.



Ferro Corp. (FOE) is a global supplier of technology-based performance materials for manufacturers. Ferro makes materials, such as enamel, ink and glaze, that enhance the performance of products in building and construction, automotive, appliances, electronics and household furnishings.



Gabelli’s trade coincides with Ferro’s ongoing plan to execute value creation strategies and cost-saving actions that are adding up. The company anticipates adjusted earnings for the full-year ending Dec. 31, 2013, to be $0.30 to $0.35 per share, compared to the previously announced range of $0.25 to $0.30. This guidance is based on preliminary first-quarter results and the progress made to date on the company’s cost-saving initiatives. For 2015, Ferro expects adjusted earnings per share of $0.90 to $1.00, compared to the previously announced range of $0.75 to $0.85.

Ferro is also trimming operational costs. As part of Ferro’s cost-saving initiative, with a goal of saving $30 million in 2013 and reaching $70 million in 2014, the company entered into a global shared services agreement with Capgemini, one of the world’s foremost providers of technology, consulting and outsourcing services, with more than 120,000 employees in 40 countries. According to Ferro, the global shared services model will enable the company to drive greater operational efficiencies and create a scalable back-office operation. Capgemini will extend Ferro’s current reach from 26 countries to 40 countries and beyond.

To allow the company to focus on its core business, Ferro also sold its pharmaceuticals business, Pfanstiehl Laboratories, to PLI Holdings Inc., an affiliate of Med Opportunity Partners LLC, for approximately $16.9 million cash, with an earn-out incentive payment of up to $8 million. The pharmaceutical divestiture follows the company’s February sale of its solar pastes assets.

Ferro’s Interim President and CEO Peter Thomas said, “The sale of our pharmaceuticals business is another important milestone in our value creation strategy. The Ferro portfolio now is more fully concentrated in our core technologies in coatings and color and glass science, polymer science, and organic synthesis…"

As of April 17, 2013, GAMCO Investors lists 792 stocks in a portfolio valued at $13.6 billion, with a quarter-over-quarter turnover at 6 percent.

For detailed insight into GAMCO Investors (GBL)

Here’s a look at Mario Gabelli’s recent top buys, sells, holdings:



GuruFocus "Real Time Picks" reports the stock purchases and sales that Gurus have made within the prior 2 weeks. The report time lag can be as short as 2 days after the date of the transaction. This feature is for Premium Members only. If you are not a Premium Member, we invite you for a 7-day Free Trial.

About the author:

Sally Jones
Sally Jones writes about Real Time Picks. She says, "I truly enjoy watching the Gurus in realtime and telling their story."

Rating: 3.0/5 (3 votes)

Comments

Please leave your comment:


Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK